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INTRODUCTION
End-stage renal disease (ESRD) patients often suffer from var-
ious cardiovascular (CV) diseases, which account for consid-
erable morbidity and mortality.1,2 In addition, diabetes melli-
tus (DM), which comprises the most common cause of ESRD,3 
is a major risk factor for CV diseases. Thus, it can be reason-
ably hypothesized that DM would play an additive role in the 
generation and advancement of CV diseases in ESRD patients 
compared to patients with ESRD due to other etiologies (non-
DM ESRD). With recent advances in diagnostic modalities for 
CV diseases and our enhanced knowledge of the CV system, we 
currently have better screening protocols for CV system even 
in subclinical stage patients. However, comprehensive inves-
tigation of the prevalence and features of CV system in ESRD 
patients with and without DM has not yet been performed. In 
this study, we assessed various structural and functional ab-
normalities in the CV system in ESRD patients and explored 
additive impact of DM on subclinical CV damage.
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Purpose: Diabetes mellitus (DM) is the most common cause of end-stage renal disease (ESRD) and an important risk factor for 
cardiovascular (CV) disease. We investigated the impact of DM on subclinical CV damage by comprehensive screening protocol 
in ESRD patients.
Materials and Methods: Echocardiography, coronary computed tomography angiogram, 24-h ambulatory blood pressure moni-
toring, and central blood pressure with pulse wave velocity (PWV) were performed in 91 ESRD patients from the Cardiovascular 
and Metabolic disease Etiology Research Center-HIgh risk cohort.
Results: The DM group (n=38) had higher systolic blood pressure than the non-DM group (n=53), however, other clinical CV risk 
factors were not different between two groups. Central aortic systolic pressure (148.7±29.8 mm Hg vs. 133.7±27.0 mm Hg, p= 0.014), 
PWV (12.1±2.7 m/s vs. 9.4±2.1 m/s, p<0.001), and early mitral inflow to early mitral annulus velocity (16.7±6.4 vs. 13.7±5.9, p= 
0.026) were higher in the DM group. Although the prevalence of coronary artery disease (CAD) was not different between the DM 
and the non-DM group (95% vs. 84.4%, p=0.471), the severity of CAD was higher in the DM group (p=0.01). In multivariate regres-
sion analysis, DM was an independent determinant for central systolic pressure (p=0.011), PWV (p<0.001) and the prevalence of 
CAD (p=0.046).
Conclusion: Diabetic ESRD patients have higher central systolic pressure and more advanced arteriosclerosis than the non-DM 
control group. These findings suggest that screening for subclinical CV damage may be helpful for diabetic ESRD patients.
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MATERIALS AND METHODS
The current study used the Cardiovascular and Metabolic dis-
ease Etiology Research Center-HIgh risk cohort (CMERC-HI) 
data, which is a prospective cohort study aimed at developing 
individual prevention strategies for patients with high risks of 
CV disease (clinicaltrial.gov NCT02003781). The CMERC-HI 
cohort enrolls patients who are 20 to 80 years old and meet at 
least one of the following inclusion criteria: high-risk hyper-
tension patients [estimated glomerular filtration rate (eGFR) 
>60 mL/min with target organ damage or eGFR ≤60 mL/min]; 
DM patients with albuminuria; anuric ESRD patients on dial-
ysis (urine output less than 200 mL/day); and relatives of acute 
myocardial infarction patients who were less than 55 years old 
for men or 65 years old for women. Exclusion criteria were a 
history of acute coronary syndrome, symptomatic coronary 
artery disease (CAD), symptomatic peripheral artery disease, 
heart failure, life expectancy less than 6 months due to non-
CV disease, women who were pregnant or nursing, and a his-
tory of contrast allergy and related side effects. Finally, 1017 
patients were enrolled between November 2013 and January 
2015 at the Severance Hospital in Seoul, Republic of Korea. This 
study was performed in a subgroup of ESRD patients with an-
uria. The Institutional Review Board of the Yonsei University 
Health System Clinical Trial Center approved the study proto-
col, and the written informed consent was obtained from all 
participants.
Twenty-four hour ambulatory blood pressure monitoring 
(ABPM) was performed using a Takeda TM-2430 instrument 
(A&D Medical, Tokyo, Japan) with readings taken every 30 min. 
ABPM measurements were done on the arm without the arte-
riovenous fistula. Daytime and nighttime periods were defined 
according to information provided by the patient. Ambulatory 
blood pressure (BP) readings were averaged for 24 hours, day-
time, and nighttime. Patients were classified according to dip-
ping pattern as follows: dippers (nighttime BP decrease >10%), 
non-dippers (nighttime BP decrease <10% and >0%) and re-
verse dippers (nighttime BP > daytime BP).
Central hemodynamics were evaluated in the sitting posi-
tion after 10 min of rest using the SphygmoCor system (AtCor 
Medical, Sydney, Australia). A high-fidelity micromanometer 
(Millar Instruments, Houston, TX, USA) was used to record 
peripheral pressure waveforms from the radial arteries as re-
ported previously.4,5 Radial artery waveforms were obtained 
from the arm without the arteriovenous fistula. The Sphygmo-
Cor system obtains the ascending aortic pressure waveform 
from the radial artery waveform using its validated mathemat-
ical transfer function. Central systolic BP, diastolic BP, pulse 
pressure, augmentation pressure, forward wave amplitude, and 
augmentation index (AI) were acquired from the aortic pres-
sure waveform analyses. Pulse pressure was calculated as the 
difference between systolic and diastolic pressures. Augmen-
tation pressure is the difference between the second and first 
systolic peak pressures, and AI was defined as the ratio of aug-
mentation pressure to aortic pulse pressure. The pulse wave 
velocity (PWV) was measured as specified previously.6 Briefly, 
electrocardiogram and carotid/femoral pulse waves were ob-
tained simultaneously to calculate the transit time using the 
foot-to-foot method. The distance traveled by the pulse wave 
was calculated by subtracting the sternal notch-right carotid 
site from right femoral site-sternal notch distances.6
In each patient, standard 2-dimensional transthoracic echo-
cardiography was performed following The American Society of 
Echocardiography guidelines.7 Left ventricular (LV) end-diastol-
ic dimension (LVEDD) and LV end-systolic dimension (LVESD), 
end-diastolic interventricular septum (IVSd), and LV posterior 
wall thickness (PWd) were measured. LV mass was calculated 
using the formula 0.8 [1.04 (IVSd+LVEDD+PWd)3-LVEDD3]+0.6 
(g) indexed to the body surface area. The LV ejection fraction 
(EF) was obtained using the modified Simpson’s method. Left 
atrial (LA) volume was measured using the biplane area-length 
method indexed to the body surface area [left atrial volume in-
dex (LAVI)]. Using Doppler, peak velocities of early (E) and late 
diastolic mitral inflow were measured. Early (E’) and late dia-
stolic mitral annulus velocity were determined at the septal cor-
ner of the mitral annulus using tissue Doppler imaging. The ratio 
of E/E’, which reflects LV filling pressure,8 was calculated. Two 
experienced echocardiologists who were unaware of the pa-
tient’s clinical information analyzed the echocardiographic data.
All testing, data acquisition, and image post-processing for 
coronary computed tomography angiogram (CCTA) were in 
accordance with the Society of Cardiovascular Computed To-
mography guidelines on CCTA acquisition.9,10 CCTA was per-
formed with multi-detector row computed tomography scan-
ners of 64 rows or greater (Aquilion ONE; Toshiba Medical 
Systems, Tokyo, Japan). Coronary arteries were evaluated ac-
cording to a 16-segment coronary artery model modified from 
the American Heart Association classification.11 Atherosclerot-
ic plaques were defined as any structure >1 mm2 within the ves-
sel lumen or adjacent to the vessel lumen that could be clearly 
distinguished from the lumen and neighboring pericardial tis-
sue or epicardial fat. CAD was defined as the presence of ath-
erosclerotic plaques in each coronary artery segment. Minimal 
CAD was defined as coronary artery segments exhibiting pl-
aques with <50% luminal narrowing, whereas significant CAD 
was defined as ≥50% luminal narrowing. The extent of signifi-
cant CAD was categorized into 1-vessel disease (VD), 2-VD, and 
3-VD. In addition, coronary artery calcium score (CACS) was 
measured in analyzable patients according to the scoring sys-
tem described by Agatston, et al.12 and Nakazato, et al.13
Continuous variables are expressed as mean±standard de-
viation after normality tests were performed for each parame-
ter to assess whether a data set was normally distributed. Cat-
egorical variables were expressed as numbers and percentages. 
Variables of the two groups were compared using two-sample 
t-tests for continuous variables and chi-squared tests and Fish-
77https://doi.org/10.3349/ymj.2017.58.1.75
Jeonggeun Moon, et al.
er’s exact tests for categorical variables. In subgroup analyses 
for evaluating impact of dialysis modality, variables were com-
pared by using the Mann-Whitney U test. Linear regression 
analyses and binary logistic regression analyses were performed 
to test the independent impact of DM on dependent vari-
ables. p<0.05 was considered statistically significant.
RESULTS
The baseline clinical characteristics of patients are summarized 
in Table 1. Patients in the DM group had higher systolic BP, and 
therefore, they took more antihypertensive medications such 
as beta-blocker and calcium channel blocker than patients in 
Table 1. Baseline Clinical Characteristics
Characteristics/Measures DM (n=38) Non-DM (n=53) p value
Demography
Age, yrs 56.0±13.0 51.2±13.6 0.096
Male, n (%) 22 (57.9) 30 (56.6) 1.000
Hypertension, n (%) 37 (97.4) 47 (88.7) 0.256
Mode of dialysis 0.894
Hemodialysis, (%) 23 (60.5) 34 (64.2)
Peritoneal dialysis, (%) 15 (39.5) 19 (35.8)
ESRD duration, yrs 16.0±25.6 13.4±13.7 0.575
Height, cm 163.4±8.9 162.4±9.3 0.590
Weight, kg 66.6±14.2 62.0±12.5 0.104
Body mass index, kg/m2 24.8±3.9 23.4±3.4 0.071
Waist, cm 87.4±11.9 83.2±9.5 0.065
Hip, cm 93.8±6.9 91.0±6.9 0.061
Thigh, cm 44.8±5.2 45.0±5.2 0.895
SBP, mm Hg 153.9±27.9 141.2±23.7 0.021
DBP, mm Hg 77.9±11.8 81.9±12.9 0.140
Heart rate, beats/min 70.8±11.8 70.8±14.0 0.994
Medications
Insulin treatment, n (%) 12 (31.6) 0 (0) <0.001
Beta-blocker, n (%) 26 (68.4) 24 (45.3) 0.048
ACEi/ARB, n (%) 26 (68.4) 31 (58.5) 0.456
CCB, n (%) 22 (57.9) 18 (34.0) 0.040
Statin, n (%) 19 (50.0) 16 (30.2) 0.090
Laboratory
Hemoglobin, g/dL 10.2±1.7 10.9±1.4 0.033
Calcium, mg/dL 8.5±1.0 9.0±0.8 0.005
Phosphate, mg/dL 5.1±1.8 4.8±1.1 0.324
Glucose, mg/dL 128.3±58.3 94.3±19.4 0.001
BUN, mg/dL 52.5±23.1 59.6±23.5 0.158
Creatinine, mg/dL 9.7±3.5 10.5±3.7 0.294
Uric acid, mg/dL 6.3±1.9 6.4±1.7 0.956
Cholesterol, mg/dL 156.9±36.3 162.5±35.8 0.470
Triglycerides, mg/dL 126.4±86.5 105.6±43.2 0.184
HDL cholesterol, mg/dL 42.8±16.0 46.2±12.3 0.265
LDL cholesterol, mg/dL 85.7±28.6 87.2±27.1 0.804
Protein, g/dL 6.4±0.9 6.6±0.7 0.206
Albumin, g/dL 3.5±0.6 3.8±0.5 0.006
Sodium, mEq/L 137.8±3.3 138.5±2.8 0.265
Potassium, mEq/L 4.7±0.8 5.0±0.9 0.190
HbA1C, % 6.6±1.4 5.2±0.3 <0.001
C-reactive protein, mg/dL 7.3±14.7 4.3±7.7 0.267
ESRD, end-stage renal disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin re-
ceptor blocker; CCB, calcium channel blocker; BUN, blood urea nitrogen; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DM, diabetes mellitus; 
HbA1C, glycosylated hemoglobin.
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the non-DM group. Other demographic findings were similar 
between the DM and non-DM groups. In laboratory findings, 
the DM group had higher fasting glucose and glycosylated he-
moglobin levels. In addition, there were statistical differences 
in hemoglobin, serum calcium, and albumin between the 
groups. However, uric acid levels and lipid profiles, which are 
well-known risk factors for CV diseases, did not differ be-
tween the two groups.
Table 2. Twenty-Four Hour-Ambulatory Blood Pressure Monitoring (ABPM) and Central Hemodynamics Assessed with Noninvasive Tonometry
DM* (n=38) Non-DM* (n=53) p value
24-hr ABPM
Dipper, n (%) 10 (27.0) 20 (38.5) 0.370
Non-dipper, n (%) 19 (51.4) 18 (34.6) 0.174
Reverse-dipper, n (%) 8 (21.6) 14 (26.9) 0.747
SBP, whole, mm Hg 149.8±23.1 142.4±23.7 0.147
DBP, whole, mm Hg 81.0±11.2 84.7±11.7 0.135
SBP, day, mm Hg 151.9±22.2 144.8±23.4 0.153
DBP, day, mm Hg 82.2±11.7 86.2±11.6 0.109
SBP, night, mm Hg 145.9±27.3 136.0±25.5 0.086
DBP, night, mm Hg 78.3±13.1 80.3±12.2 0.461
Central hemodynamics
Central aortic systolic pressure, mm Hg 148.7±29.8 133.7±27.0 0.014
Central aortic diastolic pressure, mm Hg 82.6±13.8 83.9±13.4 0.663
Augmentation index@75 30.6±12.4 29.7±16.1 0.765
Pulse wave velocity, m/s 12.1±2.7 9.4±2.1 <0.001
Pulse wave velocity standard deviation, m/s 1.1±0.7 0.7±0.6 0.002
SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus.
*One patient in the DM group and the non-DM group did not received ABPM. 
Table 3. Transthoracic Echocardiography and CCTA
Echocardiography DM (n=38) Non-DM (n=53) p value
LVEDD, mm 52.1±5.2 51.8± 5.7 0.809
LVESD, mm 34.4±4.6 34.6± 5.1 0.910
LVEF, % 65.0±7.3 64.4± 8.3 0.738
IVSd, mm 11.3±1.8 10.9±1.8 0.256
PWd, mm 11.1±1.5 10.8±1.7 0.418
LVMI, g/m2 134.6±33.7 133.1±34.2 0.837
LAVI, mL/m2 65.1±21.0 58.6±21.5 0.159
E, cm/s 0.8±0.3 0.7±0.2 0.016
A, cm/s 1.0±0.2 0.8±0.2 0.001
E’, cm/s 5.4±1.5 5.6±1.7 0.414
A’, cm/s 8.6±1.7 8.3±1.9 0.593
E/E’ 16.7±6.4 13.7±5.9 0.026
CCTA DM (n=20) Non-DM (n=32) p value
Presence of CAD, n (%) 19 (95) 27 (84.4) 0.471
Presence of significant CAD, n (%) 9 (45) 3 (9.4) 0.009
Severity of CAD, n (%) 0.010
None 1 (5.0) 5 (15.6)
Minimal CAD 10 (50.0) 24 (75)
1-vessel 6 (30) 1 (3.1)
2-vessel 2 (10) 1 (3.1)
3-vessel 1 (5) 1 (3.1)
LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; IVSd, diastolic interventric-
ular septum; PWd, diastolic posterior wall thickness; E, early diastolic mitral inflow velocity; A, late diastolic mitral inflow velocity; LVMI, left ventricular mass 
index; LAVI, left atrial volume index; E’, early diastolic mitral annulus velocity; A’, late diastolic mitral annulus velocity; CCTA, coronary computed tomography an-
giography; CAD, coronary artery disease; DM, diabetes mellitus.
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Data from 24-h ABPM, central hemodynamics, and PWV are 
shown in Table 2. Results from the 24-h ABPM were similar be-
tween the two groups. However, central aortic systolic pressure 
and PWV were significantly higher in DM patients compared to 
non-DM subjects (p<0.05). Table 3 provides the data from echo-
cardiography and CCTA examinations. In DM patients, E/E’ was 
significantly higher despite similar LV EF, indicating that DM pa-
tients have higher LV filling pressure than non-DM patients.
CCTA was performed in 52 patients, and the presence of 
atherosclerotic plaques in each coronary artery segment was 
not different between the DM and non-DM groups (95% vs. 
84.4%; p=0.471) (Table 3). However, the prevalence of signifi-
cant CAD was 23.1% (n=12); and it was higher in the DM group 
(45%) than the DM group (9.4%). As shown in Fig. 1, it is noted 
that the prevalence of significant CAD (the presence of ≥50% 
stenosis in any major coronary artery) was greater in the DM 
group (p=0.010). However, CACS, evaluated in analyzable pa-
tients (20 non-DM patients and 19 DM patients), was not dif-
ferent between the groups (non-DM group, 129.4±263.8; DM 
group, 360.3±678.7; p=0.703).
We performed statistical analyses to determine the associa-
tion of clinical variables and the independent impact of DM on 
various vascular biomarkers. These data are provided in Table 
4 and 5. The presence of DM independently determined central 
aortic pressure, PWV (Table 4), and the presence of CAD (Ta-
ble 5) in both univariate and multivariate analyses. The pres-
ence of DM had significant association with E/E’ in univariate 
analysis, however, it was not independent determinant for E/
E’ after adjustment with other variables (Table 4).
DISCUSSION
The core findings of this study are: 1) despite similar demog-
raphy, DM patients had higher central aortic systolic pressure 
and faster PWV; and 2) DM ESRD patients have more CAD and 
suffered from more severe CAD than non-DM ESRD patients. 
These results can be interpreted to indicate that DM ESRD pa-
tients have more advanced arteriosclerosis and more severe 
CAD than non-DM ESRD subjects. To the best of our knowl-
edge, the current research is the first to assess the additive im-
pact of DM on CV damage profile using a comprehensive sc-
reening protocol in ESRD patients who have a high risk of CV 
diseases. Based on the current data, we guardedly propose that 
more aggressive diagnostic work-ups and tailored manage-
ment may be helpful for DM ESRD patients.
Although data from 24-h ABPM did not differ, DM ESRD 
Table 4. Linear Regression Analyses for Independent Determinants of Central Systolic Aortic Pressure, Pulse Wave Velocity, and E/E’
Variable
Univariate model Multivariate model
β t p value β t p value
Central aortic systolic pressure
Age 0.248 1.095 0.276 0.153 0.660 0.511
Male 2.032 0.329 0.743 3.379 0.561 0.576
ESRD duration 0.006 0.040 0.968 -0.001 -0.006 0.995
Peritoneal dialysis -2.137 -0.339 0.736 -3.060 -0.474 0.637
DM etiology 14.986 2.503 0.014 15.950 2.593 0.011
Pulse wave velocity
Age 0.082 4.115 <0.001 0.072 3.783 <0.001
Male 0.523 0.896 0.372 0.522 1.064 0.290
ESRD duration 0.003 0.195 0.845 -0.001 -0.047 0.963
Peritoneal dialysis 0.269 0.449 0.654 0.615 1.176 0.243
DM etiology 2.671 5.198 <0.001 2.262 4.511 <0.001
E/E’
Age 0.143 3.009 0.003 0.120 2.392 0.019
Male -2.393 -1.829 0.071 -2.287 -1.802 0.075
ESRD duration -0.002 -0.076 0.940 0.008 0.239 0.812
Peritoneal dialysis -1.360 -1.004 0.318 -0.558 -0.401 0.689
DM etiology 2.960 1.305 0.026 2.367 1.806 0.075







Fig. 1. Coronary artery disease (CAD) severity according to the etiology 
of end-stage renal disease (ESRD). DM ESRD patients had more signifi-
cant CAD compared to the non-DM ESRD group. DM, diabetes mellitus.
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patients had significantly higher central aortic systolic pressure, 
which is a robust prognosticator for CV outcomes and is supe-
rior to conventional brachial BP.14 One potential explanation 
for this finding is more advanced arteriosclerosis in the DM 
ESRD group. This is further supported by our observation of 
faster PWV in these patients than non-DM ESRD subjects, de-
spite similar clinical characteristics. In fact, the presence of DM, 
along with age, was an independent determinant for PWV in 
our cohort. Studies have shown that hyperglycemia and hyper-
insulinemia accelerate arteriosclerosis through increased ac-
cumulation of advanced glycation end products and endothe-
lial dysfunction.15,16 In a study by Tomiyama, et al.,15 increased 
BP and increased plasma glucose levels synergistically acceler-
ated the progression of arterial stiffness in 2080 Japanese men. 
In the current investigation, we observed that the presence of 
DM independently correlated with more advanced arterial 
stiffness even in ESRD patients. This is clinically important be-
cause aortic stiffness is a strong independent predictor of CV 
mortality in subjects with end stage renal disease.17
In echocardiography examinations, however, the association 
between DM and E/E’ showed marginal significance in multi-
variate analysis, and DM patients seemed to have higher E/E’, 
which represents increased LV filling pressure.8 This result sug-
gests that: 1) DM ESRD patients might be prone to pulmonary 
congestion and/or heart failure symptoms during cardiac vol-
ume/pressure overload despite normal LV EF; and thus, 2) 
more aggressive LV unloading by renal replacement therapy 
and/or anti-heart failure medications should be considered in 
the setting of ESRD and DM.
Unexpectedly, E’ and LA volumes did not differ between the 
DM and non-DM ESRD groups. E’ reflects early diastolic LV 
longitudinal relaxation, which is more vulnerable and is an ear-
lier manifestation of cardiac dysfunction than LV radial motion, 
which is commonly expressed by LV EF in various diseases af-
fecting the heart.18 It is well known that DM patients have bl-
unted LV long-axis performances at rest19 and during exercise.20 
As previously reported, diastolic dysfunction is more advanced 
in patients with DM19-21 and ESRD;22 however, our data failed to 
show any difference in LV relaxation properties between the 
two groups. In addition, LAVI, reflecting chronicity and severity 
of diastolic function, was not different between the two groups. 
Those results are plausibly explained by: 1) the longer duration 
of ESRD in the non-DM group, 2) characteristic chronic volume 
overload status which overwhelms slight difference of myocar-
dial dysfunction in ESRD patients, and 3) E’ might be too rough 
to be used as a parameter to detect subtle differences in LV me-
chanics between the two groups. Thus, further studies are war-
ranted using a more well-balanced and larger study sample 
and newer echocardiographic technologies, such as strain 
analysis, for better evaluation of myocardial function.
Although the overall prevalence of CAD (i.e., subclinical 
CAD) was modest (23.1%) in analyzable patients based on 
CCTA, the prevalence was apparently higher in the DM group 
(45%) than non-DM group (9.4%). Our data support the notion 
that DM may have a more negative impact on CV system even 
in ESRD patients, even though ESRD itself is a powerful risk fac-
tor for CV diseases and should be regarded as a ‘CAD equiva-
lent’ condition. In DM ESRD patients, it is known that vascular 
calcification, chronic inflammation, and insulin resistance are 
kidney related CV risk factors.23 However, the current study 
showed no difference of CACS and C-reactive protein levels 
between the groups. This observation suggests that different 
pathophysiologic mechanisms such as insulin resistance might 
have roles in generation and progression of CAD between 
ESRD patients with and without DM. ESRD has a strong rela-
tionship with the development of CV diseases, including ath-
erosclerosis, due to the effects of uremia, volume/pressure 
overload of the heart and vessels, oxidative stress, and altered 
metabolism.24,25 The clinical implication of our investigation is 
that when DM, which induces oxidative stress and inflamma-
tion,21 is superimposed on ESRD, it affects the CV system in 
these patients.26 Therefore, we carefully suggest a thorough di-
agnostic work-up for the detection and characterization of 
each patient’s CV disease profile even in subclinical stages.
This study has some limitations. First, our small cohort limits 
the power of statistical analyses. Second, this is a single center 
study and included patients referred to a tertiary center. Thus, 
the current study group might not represent the entire popula-
tion of patients with ESRD. Third, because of its cross-sectional 
design, we do not have CV outcome data in this cohort, and 
only observational data analyses were possible. In addition, 
baseline clinical characteristics were not matched between the 
DM and non-DM groups, although the differences were not 
statistically significant. Further investigations with larger ESRD 
population and long-term clinical outcome are needed to ex-
plore whether the comprehensive CV screening protocol could 
Table 5. Binary Logistic Regression Analyses for Determinants of Significant Coronary Artery Disease
Variable
Univariate model Multivariate model
OR (95% CI) p value OR (95% CI) p value
Age 1.087 (1.016–1.187) 0.032 1.129 (1.015–1.312) 0.052
Male sex 10 (1.711–191.144) 0.035 1.734 (1.900–473.898) 0.031
ESRD duration 0.916 (0.803–0.999) 0.12 0.916 (0742–1.014) 0.320
Peritoneal dialysis 1.115 (0.260–4.248) 0.876 1.493 (0.157–14.696) 0.721
DM etiology 7.5 (1.883–38.445) 0.007 6.651 (1.137–51.673) 0.046
ESRD, end stage renal disease; DM, diabetes mellitus; OR; odds ratio; CI, confidence interval.
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help prevent future CV event in DM ESRD patients.
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